INS and metabolic dysfunction-associated steatohepatitis: Insulin resistance and hyperlipidemia are frequently associated with MASH in mice and humans [2,34,35]; therefore, we measured plasma levels of insulin, triglyceride (TG) and free fatty acids (FFA) four weeks after AAV8 injections.